CatalystFDA/Bio

Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

FDA approval of gene therapy for Sanfilippo Syndrome validates sector catalyst.

What changed

FDA approval of gene therapy for Sanfilippo Syndrome validates sector catalyst.

Why it matters

FDA approval of gene therapy for Sanfilippo Syndrome validates sector catalyst. — impact context not separately stored; see What changed.

Sources